Chancenoptimierung durch individualisierte ... - Tumorzentrum

More documents

Recommendations

Info

Case history details • Current staging: stable disease, drop of S100 and LDH
Case history details • Melanoma Stage IV • 03/06 NMM, TD 4,5 mm, CL IV, right thigh – surgery, negative SLN • 08/06 in transit metastasis, right thigh - surgery • 09/06 novel in-transit metastases in skin and regional lymph nodes lymph node dissection, hyperthermic perfusion of right leg with melphalan • 07/08 novel in-transit metastases in skin immunochemotherapy with local DNCB and systemic DTIC (7 x) • 04/11 novel metastases in skin, lymph nodes and both adrenal glands systemic DTIC (3 x) → progression at all sites • 07/11 immunotherapy with Yervoy (Ipilimumab) 2x • 09/11 inflammation of pituitary gland with siADH syndrome • 10/11 steroid induced psychosis
Page 1 and 2: Melanom 2012: Chancenoptimierung du
Page 3 and 4: Systemtherapie des Melanoms bis 201
Page 7 and 8: Targeted Therapy - Inhibitoren Boss
Page 9 and 10: Kinaseinhibitor PLX4032 (Vemurafeni
Page 11 and 12: BRAF + Tumorlast +++ Dynamik +++ Ki
Page 13 and 14: Systemtherapie im Stadium IV Melano
Page 15 and 16: Systemtherapie im Stadium IV Melano
Page 17 and 18: Wirkmechanismus von Ipilimumab Die
Page 19 and 20: ASCO 2010 - Immuntherapie 19
Page 21: Case history details • MRT showin
Page 25 and 26: DNCB / DTIC Immunchemotherapie CR 7
Page 27 and 28: Systemtherapie Stadium IV Melanom B
Page 29 and 30: Targeted Therapy: Sorafenib 12.01.2
Page 31 and 32: MM Stadium IV: Therapieoptionen fü
Page 33 and 34: Therapieoptionen des Uvea Melanoms
Page 35: Melanom: Prognostische Faktoren 35
Page 38 and 39: Individualisierte Melanomtherapie G
Page 42 and 43: Melanom - Zukunft Protein und RNA A
Page 44 and 45: Dank - dem GMP Team B. Schuler-Thur
Page 46 and 47: Dank - allen Mitarbeitern der MM Am

Chancenoptimierung durch individualisierte ... - Tumorzentrum

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?